NasdaqGS:RGENLife Sciences
Moderated 2026 Guidance and Sector Weakness Might Change The Case For Investing In Repligen (RGEN)
In Q1 2026, institutional investors reported that Repligen’s updated 2026 guidance, including moderated revenue and organic growth expectations, weighed on fund performance as market sentiment toward life-sciences tools weakened.
An interesting wrinkle is that some investors highlighted Repligen’s lack of exposure to pressured National Institutes of Health funding and management’s earlier bullish tone, underscoring how broader sector mood can influence sentiment even when company-specific...